Efficacy of Vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: An open label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol, 2019, 3: PO.18.00266. [8]Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in ...
[7]DING X, ZHANG Z L, JIANG T, et al. Clinicopathologic characteristics and outcomes of Chinese patients with non-small cell lung cancer and BRAF mutation[J]. Cancer Med, 2017,6(3): 555-562. [8]Planchard D, et al. J Thorac Oncol. 2022 Jan;17(1):103-115. [9]Planchard D. et ...
1. Facchinetti F, Lacroix L, Mezquita L, et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. Eur J Cancer, 2020, 132: 211-223. 2. Dagogo-Jack I, Martinez P,...
1. Facchinetti F, Lacroix L, Mezquita L, et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. Eur J Cancer, 2020, 132: 211-223. 2. Dagogo-Jack I, Martinez P, Yeap BY, et al. Impact of BRAF Mutation Class on Disease Characteristics...
[7]Subbiah V, Gervais R, Riely G, et al. Efficacy of Vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: An open label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol, ...
【关键词】 肺肿瘤; 非小细胞肺癌; BRAF; BRAF V600; BRAF 抑制剂; 丝裂原活化蛋 白激酶抑制剂 DOI:10.3760 / cma.j.cn112152⁃20230117⁃00030 Expert consensus on the diagnosis and treatment in advanced non⁃small cell lung cancer with BRAF mutation in China Lung Cancer Professional Committee...
Although BRAF mutations are commonly seen in melanoma and papillary thyroid cancer, other cancers may also harbour BRAF mutations. We aimed to investigate the prevalence and clin-icopathological features of BRAF mutations in non-small cell lung cancer (NSCLC).MethodsTumours were genotyped using the ...
Do KH, Nguyen TV, Nguyen Thi Bich P, etc. Successful first-line pembrolizumab combined with chemotherapy in PD-L1-negative non-small cell lung cancer with a rare BRAF mutation: a case report and review of the literature [J]. Case reports in Respirology, 2023, 11(6): e01155 . ...
[8]Cui G, Liu D, Li W, et al. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer[J]. Medicine, 2017, 96(14). *"医学界"力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
非小细胞肺癌(non-small cell lung cancer, NSCLC)是临床最常见的肺癌类型,占所有肺癌的85%。BRAF是丝裂原活化蛋白激酶(mitogen-activated protein kinase, MAPK)/细胞外信号调节激酶(extracellular signal-regulated kinases, ERK)信号通路的关键分子。BRAF突变最初在黑色素瘤中发现,随后在结直肠癌、甲状腺乳头状癌和...